Research Progress of PR, NLR, SII and HALP in Prognostic Evaluation of Lung Cancer

炎症在肺癌发生、发展和预后中扮演着重要的角色。作为肿瘤微环境的重要组成部分，炎症细胞及其介导的免疫反应与肺癌的预后密切相关。肺癌作为全球发病率和死亡率最高的恶性肿瘤之一，其预后评估始终是临床诊疗的关键环节。近年来，随着肿瘤微环境研究的深入，血小板/淋巴细胞(PLR)、中性粒细胞/淋巴细胞(NLR)、血小板 × 中性粒细胞/淋巴细胞(SII)、血红蛋白 × 白蛋白 × 淋巴细胞/血小板计数(HALP)等新型炎症标志物逐渐成为研究热点。这些指标不仅检测简便、成本低廉，还能动态反映机体免疫失衡与炎症状态，在肺癌的预后评估中展现出独特价值。本文将围绕这些标志物在肺癌预后中的研究进展展开综述。Inflammation plays an important role in the occurrence, development, and prognosis of lung cancer. As an important component of the tumor microenvironment, inflammatory cells and their mediated immune responses are closely related to the prognosis of lung cancer. Lung cancer is one of the malignant tumors with the highest incidence rate and mortality in the world, and its prognosis evaluation is always a key link in clinical diagnosis and treatment. In recent years, with the in-depth study of the tumor microenvironment, novel inflammatory markers such as the platelet/lymphocyte (PLR), neutrophil/lymphocyte (NLR), platelet × neutrophil/lymphocyte (SII), and hemoglobin × albumin × lymphocyte/platelet count (HALP) have gradually become research hotspots. These indicators are not only easy to detect and cost-effective, but also dynamically reflect the immune imbalance and inflammatory status of the body, demonstrating unique value in the prognosis evaluation of lung cancer. This article will review the research progress of these biomarkers in the prognosis of lung cancer.